Novo Nordisk
NVO
#21
Rank
ยฃ362.16 B
Marketcap
ยฃ83.33
Share price
2.57%
Change (1 day)
0.63%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total debt

Total debt on the balance sheet as of September 2024 : ยฃ6.75 Billion

According to Novo Nordisk's latest financial reports the company's total debt is ยฃ6.75 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Novo Nordisk - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31ยฃ3.13 B2.29%
2022-12-31ยฃ3.06 B2.13%
2021-12-31ยฃ3.00 B139.3%
2020-12-31ยฃ1.25 B145.01%
2019-12-31ยฃ0.51 B724.61%
2018-12-31ยฃ62.16 M-69.24%
2017-12-31ยฃ0.20 B668.97%
2016-12-31ยฃ26.27 M-75.24%
2015-12-31ยฃ0.10 B40.48%
2014-12-31ยฃ75.53 M213%
2013-12-31ยฃ24.13 M-56.01%
2012-12-31ยฃ54.85 M-42.63%
2011-12-31ยฃ95.6 M-62.82%
2010-12-31ยฃ0.25 B55.61%
2009-12-31ยฃ0.16 B-44.45%
2008-12-31ยฃ0.29 B121.14%
2007-12-31ยฃ0.13 B-1.88%
2006-12-31ยฃ0.13 B-44.53%
2005-12-31ยฃ0.24 B52.72%
2004-12-31ยฃ0.16 B-1.2%
2003-12-31ยฃ0.16 B31.68%
2002-12-31ยฃ0.12 B-25.66%
2001-12-31ยฃ0.16 B-1.56%
2000-12-31ยฃ0.16 B-4.64%
1999-12-31ยฃ0.17 B-25.24%
1998-12-31ยฃ0.23 B-12.2%
1997-12-31ยฃ0.27 B40.78%
1996-12-31ยฃ0.19 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
ยฃ52.73 B 680.55%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ24.63 B 264.63%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ40.68 B 502.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ20.15 B 198.32%๐Ÿ‡ซ๐Ÿ‡ท France